Nasdaq:US$16.21 (-0.64) | HKEX:HK$26.45 (+1.00) | AIM:£2.72 (+0.05)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Jun 2012

ASCO 2012: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors